RecruitingNot ApplicableNCT07243600

Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment

Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment (INHANCE-MCI)

Sponsor

Posit Science Corporation

Enrollment

84 participants

Start Date

Jul 17, 2026

Study Type

INTERVENTIONAL

Conditions

Mild Cognitive Impairment

Summary

This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).

Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Computerized executive function cognitive training and Computerized speed-based cognitive training for people with mild cognitive impairment. The study is currently recruiting participants at 1 location. People eligible for this study include aged 65 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERComputerized speed-based cognitive training

Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.

OTHERComputerized executive function cognitive training

Thirty minutes of training on computerized exercises that target executive function.

Locations(1)

Montreal Neurological Institute-Hospital

Montreal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07243600

Related Trials

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression

NCT077175671 location